-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche Expands Alzheimer’s Pipeline With New Phase II TARBELA-AD Trial Of Oral NLRP3 Inhibitor RG6434, To Present Trontinemab, PrevenTRON, Elecsys Blood Test Data At CTAD November 16-19

Benzinga·11/10/2026 06:25:30
Listen to the news
  • Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers 
  • Phase III PrevenTRON study design specifics for trontinemab in preclinical Alzheimer’s disease, which has commenced enrolment
  • Phase II TARBELA-AD study design for the investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease, representing a novel mechanism of action targeting neuroinflammation
  • Global clinical and health economic data on the Elecsys® pTau217 and Elecsys pTau181 blood tests supporting accessible, timely diagnosis